Abbott wins FDA nod for first dual-chamber leadless pacemaker

Abbott (NYSE: ABT)+
announced today that it received FDA approval for its Aveir dual-chamber leadless pacemaker system.
The approval marks the first such nod for a dual-chamber leadless pacing system for treating abnormal or slow heart rhythms. According to Abbott, more than 80% of people who need a pacemaker require pacing in two chambers of the heart — the right atrium and right ventricle.